	US 11,714,089 B2
	Combination of markers for diagnosing cancer
Nadir Arber, Tel-Aviv (IL); Shiran Shapira, Petach-Tikva (IL); and Diana Kazanov, Rishon-LeZion (IL)
Assigned to The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center, Tel-Aviv (IL)
Appl. No. 16/615,423
Filed by The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center, Tel-Aviv (IL)
PCT Filed May 21, 2018, PCT No. PCT/IL2018/050550 § 371(c)(1), (2) Date Nov. 21, 2019, PCT Pub. No. WO2018/216006, PCT Pub. Date Nov. 29, 2018.
Claims priority of provisional application 62/509,118, filed on May 21, 2017.
Prior Publication US 2020/0174004 A1, Jun. 4, 2020
Int. Cl. G01N 33/574 (2006.01); A61K 45/06 (2006.01)

CPC G01N 33/57492 (2013.01) [A61K 45/06 (2013.01)]

11 Claims

1. A method treating a cancer or a pre-malignant lesion in a subject in need thereof, the method comprising:

(a) diagnosing a cancer or a pre-malignant lesion in the subject by determining a level of expression of CD24 and CD11b on leukocytes comprised in a biological sample of the subject so as to determine a number of leukocytes having a CD24⁺CD11b⁻ signature and not having a CD24⁺CD11b⁺ signature, and wherein said number of leukocytes having a CD24⁺CD11b⁻ signature above a predetermined threshold is indicative of said cancer or said pre-malignant lesion; and

(b) administering a therapeutic agent for the treatment of the cancer or the pre-malignant lesion to the diagnosed subject,

thereby treating cancer or a pre-malignant lesion in the subject in need thereof.